Recruiting Spinal Muscular Atrophy Studies in Jacksonville
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (...
A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
The purpose of this study is to compare the clinical benefit of the combination of BMS-986504 (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus p...
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19de...
DAREONâ„¢-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard tre...
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues...
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participan...
About Spinal Muscular Atrophy Clinical Trials in Jacksonville
Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder that causes loss of motor neurons, leading to progressive muscle weakness and atrophy. It is the leading genetic cause of infant death. Revolutionary gene therapies and SMN-enhancing drugs have transformed treatment.
There are currently 6 spinal muscular atrophy clinical trials recruiting participants in Jacksonville, FLORIDA. These studies are seeking a combined 2,461 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Bristol-Myers Squibb, Boehringer Ingelheim and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Spinal Muscular Atrophy Clinical Trials in Jacksonville — FAQ
Are there spinal muscular atrophy clinical trials in Jacksonville?
Yes, there are 6 spinal muscular atrophy clinical trials currently recruiting in Jacksonville, FLORIDA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Jacksonville?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Jacksonville research site will contact you about next steps.
Are clinical trials in Jacksonville free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Jacksonville studies also compensate for your time and travel.
What spinal muscular atrophy treatments are being tested?
The 6 active trials in Jacksonville are testing new therapies including novel drugs, biologics, and treatment approaches for spinal muscular atrophy.
Data updated March 2, 2026 from ClinicalTrials.gov